PCI Pharma Services Announces the Acquisition of Bellwyck Pharma Services to Expand Global Clinical Trial Services into Canada and Continental Europe
PCI Pharma Services (PCI) , a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, today announced the acquisition of Bellwyck Pharma Services (Bellwyck), headquartered in Toronto, Canada. With 25 years of experience, Bellwyck is a leader in primary and secondary packaging and labeling for clinical trial and commercial drug markets. The acquisition will add four GMP-compliant facilities to the PCI network in the U.S., Germany and Canada. With Canada and Germany ranked third and fourth in the world for total number of clinical trials, respectively,1 this acquisition greatly enhances the global reach of PCI’s services in key markets.
“We are thrilled to welcome the Bellwyck team into the PCI family,” said Salim Haffar, chief executive officer, PCI Pharma Services. “Their passion for patients, talented team and innovative approach to client challenges is perfectly aligned to our purpose and global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world. We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities.”
Bellwyck’s clinical and commercial supply chain solutions mirror PCI’s existing core capabilities including extensive clinical trial packaging, labeling and logistics for Phase I-IV studies as well as full-service commercial packaging. With the addition of Bellwyck, PCI will now feature 25 GMP facilities across North America, Europe, and Asia-Pacific, employing over 3,700 highly trained associates.
“We are delighted that Bellwyck is joining the PCI team and anticipate a seamless integration for our employees and clients,” said Jeff Sziklai, chief executive officer, Bellwyck Pharma Services. “We have a shared focus on innovation, quality, exceptional service and our employees. Joining forces with a global industry leader, such as PCI, is a great step forward for Bellwyck. We look forward to helping accelerate the global growth of PCI’s clinical business, leveraging our reputation for innovative, customized clinical trial solutions for our clients.”
The acquisition of Bellwyck to establish a presence in Canada and Germany further underscores PCI’s global strategy and commitment to be the partner of choice to meet the market needs of its clients. The addition of Bellwyck will mark PCI’s third acquisition outside of the U.S. in three years, demonstrating PCI’s continued commitment to growth, geographic expansion and serving patients across the world.
PCI, headquartered in Philadelphia, PA, is principally owned by Partners Group on behalf of its clients, with partner investors Thomas H. Lee Partners and Frazier Healthcare.
Bellwyck engaged PricewaterhouseCoopers Corporate Finance Inc. as their financial advisor on this transaction.
1 ClinicalTrials.gov Web site. Search of All Trials. Bethesda (MD): National Library of Medicine (US). Available: https://clinicaltrials.gov/ct2/results/map . Accessed 2020 January 27.
About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-PERSONALIS18.2.2020 22:07:10 CET | Press release
Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference
FRANCHISE-PARTNERS18.2.2020 22:02:10 CET | Press release
Franchise Partners Outlines Opportunities for Value Creation at Kirin Holdings
FL-PHILIP-STEIN18.2.2020 21:02:09 CET | Press release
Philip Stein Sleep Bracelet Clinically Proven To Improve Sleep and Overall Wellness, A Drug-Free Approach To Sleep Wellness
BERMUDA-BUSINESS-DEVLPMT18.2.2020 20:24:08 CET | Press release
Bermuda’s ‘White List’ Status Confirmed by the EU and Applauded by Industry
SUMITOMO-SHI-FW18.2.2020 18:14:15 CET | Press release
HELEN and Sumitomo SHI FW (SFW) Combine Forces: SFW CFB Boiler Technology to be Utilized at Vuosaari Bioenergy Plant
CAYMAN-GOVT-EFFORTS18.2.2020 17:12:04 CET | Press release
Cayman Finance Supports Government’s Efforts to Be Delisted by the European Union
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom